Related Experiment Video
Updated: Dec 7, 2025
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases
Yingjian Deng1, Guiyang Li1, Dong Chang1
1Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
Insights
Residual cardiovascular risk persists despite statin therapy for dyslipidemia. The inflammatory biomarker YKL-40 shows promise for monitoring treatment and predicting events in cardio-metabolic disorders.
Area of Science:
- Cardiology
- Biochemistry
- Inflammation Research
Background:
- Dyslipidemia, often part of metabolic syndrome (insulin resistance, hypertension, obesity), poses significant cardiovascular risk.
- Statins effectively lower LDL-C but residual risk for atherosclerosis remains a challenge.
- Novel biomarkers are needed to monitor treatment and predict cardiovascular events.
Purpose of the Study:
- To review the role of YKL-40 in the pathogenesis of cardio-metabolic disorders.
- To explore YKL-40 as a potential biomarker for athero-protective therapy monitoring.
Main Methods:
- Literature review on YKL-40's involvement in inflammatory and cardio-metabolic diseases.
- Analysis of evidence linking YKL-40 to disease severity, prognosis, and survival.
Main Results:
- YKL-40 is implicated in inflammatory diseases and cardio-metabolic disorders.
- Evidence suggests YKL-40 may be useful in evaluating disease severity and prognosis.
- YKL-40 has potential as a biomarker for monitoring athero-protective strategies.
Conclusions:
- YKL-40 plays a role in the pathogenesis of cardio-metabolic disorders.
- YKL-40 is a promising novel biomarker for assessing disease status and treatment effectiveness.
- Further research into YKL-40 could improve cardiovascular event prediction and management.
Abstract:
Dyslipidaemia is associated with numerous health problems that include the combination of insulin resistance, hypertension and obesity, ie, metabolic syndrome. Although the use of statins to decrease serum low density lipoprotein cholesterol (LDL-C) has been an effective therapeutic in treating atherosclerosis, the persistence of high atherosclerotic risk, ie, residual risk, is notable and is not simply explained as a phenomenon of dyslipidaemia. As such, it is imperative that we identify new biomarkers to monitor treatment and more accurately predict future cardiovascular events. This athero-protective strategy includes the assessment of novel inflammatory biomarkers such as YKL-40. Recent evidence has implicated YKL-40 in patients with inflammatory diseases and cardio-metabolic disorders, making it potentially useful to evaluate disease severity, prognosis and survival. In this review, we summarize role of YKL-40 in the pathogenesis of cardio-metabolic disorders and explore its use as a novel biomarker for monitoring athero-protective therapy.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...